Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$18.90
▲ $0.04 (+0.2%)
Market data updated: 09/29 03:23 AM
News analyzed: 09/29/2026
Market Cap
$29.44B
Day Range
$18.66 - $19.00
52-Week Range
$12.99 - $19.10
Beta
—
Next Earnings
28.10.2026
Support
$16.30
Resistance
$19.10
TAK is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+28.7% (1Y)
🟡 Moderate
Strengths: 9/13 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟢 Bullish
Technical Trend
🟢 Bullish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Daily volatility (ATR)
ATR: 1.5% of price
Risk
Biggest negative driver
Calmar Ratio (return vs. drawdown)
Calmar: 0.33 (3y annualized return 6.6% / max drawdown 20.1%)
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 3 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 3
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
Takeda Pharmaceutical's (TAK) overall investor score of 76 reflects a balanced profile with notable technical strength but mixed fundamental and risk factors. The technical category scores exceptionally high at 86, driven by the stock’s sustained position above both the 50-day and 200-day moving averages, a bullish MACD histogram, and a healthy RSI of 62.9—all signaling robust upward momentum. However, the news category lags at 62, with mixed headlines dominated by neutral developments, such as royalty discussions and market outlooks, though a positive mention of late-stage drug candidates provides a slight counterbalance. Risk remains the weakest link at 50, highlighted by a modest average true range (ATR) and a Calmar ratio of 0.28, indicating moderate volatility and a historical drawdown risk of 22.8%. The declining trading volume despite price gains further raises caution about potential weakening interest or liquidity concerns.
The stock price is firmly above both the 50-day and 200-day moving averages, accompanied by a positive MACD histogram and an RSI of 62.9, all of which indicate strong bullish momentum and overbought but sustainable conditions.
This technical alignment suggests a favorable short-to-medium-term outlook, reinforcing investor confidence in continued upward movement.
News coverage is predominantly neutral, with only one positive mention of late-stage drug candidates, while other articles focus on share repurchases and royalty discussions without clear directional impact.
The lack of strong positive news may limit upside catalysts, while neutral developments could either sustain or fail to excite investor sentiment.
The ATR of 1.6% and a Calmar ratio of 0.28 (with a 22.8% historical drawdown) indicate moderate volatility and a risk of significant short-term declines, particularly given the declining volume trend.
These metrics highlight potential downside exposure, especially if market conditions shift or investor enthusiasm wanes.
StockIQ conclusion
Takeda Pharmaceutical’s (TAK) profile is characterized by strong technical momentum but tempered by neutral news coverage and moderate risk factors. While the stock’s position above key moving averages and positive MACD suggest short-term resilience, concerns about declining volume and historical volatility underscore potential downside risks. The company’s pipeline and share repurchase program offer long-term positives, but the absence of strong near-term catalysts may limit upside potential. Investors should monitor clinical developments and volume trends for clearer directional signals.
Written automatically from the computed data shown on this page only — not investment advice.
🗓️ What Changed This Week
as of 09/22/202673
This Week
68
7D Ago
↑ +5
Improving
Technical
75
7D Ago: 88
↓ -13
News
80
7D Ago: 26
↑ +54
Risk
50
7D Ago: 50
→ 0
Biggest Improvements
Biggest Declines
📊 Score History
73
Today
80
30D
—
90D
—
1Y
🔎 What Changed (vs. 30 days ago)
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
33d ago · $18.24
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
33d ago · $18.24
Evidence: 10 bullish / 2 bearish technical signals agreeing
What happened after
34d ago · $18.35
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
34d ago · $18.35
Evidence: 10 bullish / 2 bearish technical signals agreeing
What happened after
🐂🐻 Investment Thesis
🐂 Bull Case
⚖️ Base Case
73 / 100
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🕰️ StockIQ Time Machine
What did StockIQ know — and when? Pick a date from the real accumulated history.
As of August 26, 2026
Then
82
$18.35
Now
73
$18.90
What happened since
Signals detected by this date
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
No data available
Quality
No data available
Value
No data available
Momentum
75
Risk
50
Sentiment
80
Fundamental
No data available
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Everyone's writing about Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock). News trend score: 80. Reason: 10 of the last 20 articles are positive, versus 5 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
24
🎯 Conviction (vs. Emotion)
50
Psychology
75
Fundamentals
—
Technical
75
Valuation
—
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Extreme momentum, price far above its moving average, and a large premium over fair value.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Price (3M)
+19%
Market Narrative
60
Fundamental Reality
50
Narrative Gap
+10
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
Market behavior suggests psychological focus around key technical reference points, evidenced by Anchoring scoring a dominant 58 as trading approaches within 2.1% of resistance. Meanwhile, Herding behavior at 49 is consistent with the stock's -1.4% move aligned with peer declines averaging -0.9%. Anchoring bias appears active as price action clusters near resistance while news sentiment remains neutral at 50/100. A key open question is whether market behavior will shift if trading moves significantly away from this resistance anchor.
Updated: 09/06/2026, 02:16 PM
What could change this?
👥 What the crowd believes
"Takeda Pharmaceutical Company Limited (TAK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript"
📈 13D Investor Psychology
Signal classification confidence: Medium (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Morgan Housel — 83/100
🔴 Weakest match
Samuel Armstrong Nelson — 20/100
🗣️ Why do they disagree?
Based on his documented principles, the model estimates that Jesse Livermore’s approach yields the highest score (65) but his verdict still advises staying out because there is no clear trend. The efficient‑market perspective (58) remains mixed, reflecting that the evidence for outperformance versus a broad index is weak. The Graham, Fisher, and Lynch scores are all 50, yet each verdict cites insufficient data—balance‑sheet/valuation for Graham, fundamentals for Fisher, and growth metrics for Lynch—so their assessments are limited by missing inputs. Howard Marks scores 48 and offers a mixed view, noting a solid business but already high expectations, which illustrates how his focus on macro‑outlook tempers the positive fundamentals.
Morgan Housel
The Psychology of Money (2020)
🟢 83
The kind of quiet compounder a patient holder could actually stick with
Key question
Could I live with this volatility long enough for compounding to actually work?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟢 71
Not enough dividend/growth data for a real Smith read
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 64
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟡 57
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 55
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 50
Not enough balance-sheet/valuation data for a real Graham read
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 50
Not enough fundamentals data for a real Fisher read
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Peter Lynch
One Up on Wall Street (1989)
🟡 50
Not enough growth data for a real Lynch read
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Walter Bagehot
Lombard Street (1873)
🟡 50
Not enough balance-sheet data for a real Bagehot read
Key question
Does this company have enough liquidity to survive real stress?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 50
Not enough valuation data for a real Enterprising-Graham read
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 47
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 46
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 43
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 41
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 20
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🔴 20
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Based on the last 285 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (8 bullish · 2 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Low confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Total dividend per share paid each year, over the last 5 years.
| Ex-Dividend Date | Amount per Share |
|---|---|
| 31.3.2025 | $0.339 |
| 30.3.2025 | $0.339 |
| 30.9.2024 | $0.326 |
| 29.9.2024 | $0.326 |
| 27.3.2024 | $0.292 |
| 26.3.2024 | $0.292 |
Sentiment based on basic keywords (not AI) — 10 positive, 5 neutral, 5 negative out of the last 20 articles.
Yahoo · 28.9.2026
Yahoo · 25.9.2026
SeekingAlpha · 24.9.2026
Yahoo · 22.9.2026
Business Wire · 22.9.2026
Benzinga · 21.9.2026
Zacks · 18.9.2026
Yahoo · 18.9.2026
MT Newswires · 18.9.2026
SeekingAlpha · 18.9.2026
Business Wire · 18.9.2026
Yahoo · 18.9.2026
Insider Monkey · 17.9.2026
Yahoo · 17.9.2026
Benzinga · 17.9.2026
Simply Wall St. · 16.9.2026
Yahoo · 16.9.2026
PR Newswire · 15.9.2026
Yahoo · 15.9.2026
GlobeNewswire · 15.9.2026
StockIQ doesn't currently have enough real data to compute a reliable score for Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) — only 3 of 7 categories are available right now. Rather than show a misleading number, this page shows which data is missing instead.
StockIQ doesn't give buy/sell recommendations — and for TAK specifically, there currently isn't enough real data (only 3 of 7 categories available) to state even a factual score reliably. Check back once more data is available.
TAK's technical score is 75/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: ATR: 1.5% of price; Price is above the 50-day average; Price is above the 200-day average.
Based on the real signals StockIQ computed: Calmar: 0.33 (3y annualized return 6.6% / max drawdown 20.1%); MACD histogram is negative — falling momentum; CMF 20 days: -0.26.
Yes — TAK has a real recorded dividend payment history on StockIQ. See the Dividends section on this page for the actual per-share amounts and dates.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 25 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Duprey Lauren Rusckowski | Open Market Sale | 14.9.2026 | 191,522 | -34,535 | $18.54 |
| Duprey Lauren Rusckowski | Open Market Sale | 14.9.2026 | 34,535 | -34,535 | $18.54 |
| Plump Andrew Stewart | Open Market Sale | 2.9.2026 | 145,465 | -116,191 | $18.49 |
| Plump Andrew Stewart | Open Market Sale | 2.9.2026 | 116,191 | -116,191 | $18.49 |
| Plump Andrew Stewart | Open Market Sale | 19.8.2026 | 261,656 | -19,651 | $18.49 |
| Plump Andrew Stewart | Open Market Sale | 19.8.2026 | 19,651 | -19,651 | $18.49 |
| Greenway Nicola Deidre Petal | Open Market Sale | 18.8.2026 | 40,049 | -12,980 | $18.11 |
| Greenway Nicola Deidre Petal | Open Market Sale | 18.8.2026 | 12,980 | -12,980 | $18.11 |
| Shannon Elaine Mary | Open Market Sale | 11.8.2026 | 67,311 | -20,363 | $17.55 |
| Plump Andrew Stewart | Open Market Sale | 10.8.2026 | 165,393 | -165,393 | $17.10 |
| Furney Natalie Anne Marie | Open Market Sale | 10.8.2026 | 30,868 | -30,868 | $17.10 |
| Farajallah Awny Samaan Botros | Open Market Sale | 10.8.2026 | 14,006 | -14,006 | $17.10 |
| Duprey Lauren Rusckowski | Open Market Sale | 10.8.2026 | 47,586 | -47,586 | $17.10 |
| Shannon Elaine Mary | Open Market Sale | 10.8.2026 | 3,978 | -3,978 | $17.10 |
| Pignagnoli Agosti Marcello | Open Market Sale | 10.8.2026 | 22,957 | -22,957 | $17.10 |
| Bitetti Teresa Marie | Open Market Sale | 10.8.2026 | 50,012 | -50,012 | $17.10 |
| Kim Julie So-Young | Open Market Sale | 10.8.2026 | 89,090 | -89,090 | $17.10 |
| Platford Giles Richard | Open Market Sale | 10.8.2026 | 31,083 | -31,083 | $17.10 |
| Greenway Nicola Deidre Petal | Open Market Sale | 10.8.2026 | 6,774 | -6,774 | $17.10 |
| Ricci Gabriele | Open Market Sale | 10.8.2026 | 25,088 | -25,088 | $17.10 |
| Pacheco Rhonda Janice | Open Market Sale | 10.8.2026 | 16,901 | -16,901 | $17.10 |
| Ibrahim Ramy Riad Ahmed | Open Market Sale | 10.8.2026 | 7,277 | -7,277 | $17.10 |
| Ibrahim Ramy Riad Ahmed | Open Market Sale | 10.8.2026 | 102,588 | -7,277 | $17.10 |
| Duprey Lauren Rusckowski | Open Market Sale | 10.8.2026 | 226,057 | -47,586 | $17.10 |
| Pignagnoli Agosti Marcello | Open Market Sale | 10.8.2026 | 176,977 | -22,957 | $17.10 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
4,204,915 shares short as of 2026-09-15 · vs. 4,088,761 on 2026-08-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
29.9% of trading volume this week was short selling, vs. 30.4% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology